PTPI Stock Overview
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Petros Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.69 |
| 52 Week High | US$9.54 |
| 52 Week Low | US$0.66 |
| Beta | 2.24 |
| 1 Month Change | -53.06% |
| 3 Month Change | -38.39% |
| 1 Year Change | -89.47% |
| 3 Year Change | -97.74% |
| 5 Year Change | n/a |
| Change since IPO | -98.27% |
Recent News & Updates
Shareholder Returns
| PTPI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -22.1% | -2.2% | -3.7% |
| 1Y | -89.5% | 11.6% | 20.5% |
Return vs Industry: PTPI underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: PTPI underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| PTPI volatility | |
|---|---|
| PTPI Average Weekly Movement | 16.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PTPI's share price has been volatile over the past 3 months.
Volatility Over Time: PTPI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | n/a | www.petrospharma.com |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Petros Pharmaceuticals, Inc. Fundamentals Summary
| PTPI fundamental statistics | |
|---|---|
| Market cap | US$4.85m |
| Earnings (TTM) | -US$13.81m |
| Revenue (TTM) | US$5.82m |
0.8x
P/S Ratio-0.3x
P/E RatioIs PTPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTPI income statement (TTM) | |
|---|---|
| Revenue | US$5.82m |
| Cost of Revenue | US$1.63m |
| Gross Profit | US$4.19m |
| Other Expenses | US$18.01m |
| Earnings | -US$13.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 71.98% |
| Net Profit Margin | -237.26% |
| Debt/Equity Ratio | 64.2% |
How did PTPI perform over the long term?
See historical performance and comparison